Moderna Lowers Full-Year Revenue Outlook, Plans to Cut Cash …

Moderna (MRNA) shares fell intraday Monday after the company cut its full-year revenue outlook while the drugmaker aims to reduce cash costs by $1 billion in 2025 amid its ongoing cost …

$1
OFF

Moderna Lowers Full-Year Revenue Outlook, Plans To Cut Cash …

2 weeks from now

Moderna (MRNA) shares fell intraday Monday after the company cut its full-year revenue outlook while the drugmaker aims to reduce cash costs by $1 billion in 2025 amid its ongoing cost …

msn.com

$1
OFF

Moderna Cuts 2025 Sales Forecast By $1 Bln On Weak Vaccine …

2 weeks from now

2 days ago · It expects $1.5 billion to $2.5 billion in annual revenue, mostly in the second half, which is lower than a prior forecast of $2.5 billion to $3.5 billion and below market expectation …

reuters.com

17%
OFF

Moderna Stock Plunges Nearly 17% After Company Lowers 2025 …

2 weeks from now

3 days ago · Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.

cnbc.com

$1
OFF

Moderna Surprises The Street By Predicting A Bigger-than …

2 weeks from now

2 days ago · The company also said it was speeding up and expanding a cost-cutting plan. It expects to cut cash costs by $1 billion in the new year, with additional cuts planned in 2026. …

apnews.com

$1
OFF

Moderna Surprises The Street By Predicting A Bigger-than …

2 weeks from now

3 days ago · It expects to cut cash costs by $1 billion in the new year, with additional cuts planned in 2026. Moderna pulled in most of its revenue last year from its COVID-19 vaccine, Spikevax, …

go.com

$1
OFF

Moderna Expects Lower Annual Sales, Expands Cost-Cutting …

2 weeks from now

3 days ago · Moderna targets ten product approvals by 2027 while cutting R&D costs by $1.1 billion. FY2024 revenue reached $3 billion-$3.1 billion, with $9.5B in cash reserves.

benzinga.com

$1
OFF

Moderna Surprises The Street By Predicting A Bigger-Than …

2 weeks from now

2 days ago · It expects to cut cash costs by $1 billion in the new year, with additional cuts planned in 2026. Moderna pulled in most of its revenue last year from its COVID-19 vaccine, Spikevax, which brought ...

usnews.com

$1
OFF

Moderna Cuts Sales Forecast On Weaker Vaccine Demand - Yahoo …

2 weeks from now

2 days ago · Moderna shares slumped Monday on the companies downgraded 2025 outlook. ... Moderna cut its 2025 ... and aim to reduce 2025 cash costs by $1 billion with a plan for an …

yahoo.com

8%
OFF

Moderna's Spending Cuts, Pipeline Shakeup Leave Doubts About A …

2 weeks from now

Sep 13, 2024 · One key concern: The company's full-year 2025 revenue guidance, issued Thursday, is nearly 8% lower, at the midpoint, than its full-year 2024 guidance - which was …

morningstar.com

$6
OFF

Moderna Issues Outlook For FY25 And Beyond, Cuts R&D Budget; …

2 weeks from now

Sep 12, 2024 · Moderna Issues Outlook For FY25 And Beyond, Cuts R&D Budget; Stock Down In Pre-market ... Moderna plans to break even on an operating cash cost basis with $6 billion in …

businessinsider.com

$6
OFF

Moderna Forecasts Lower Sales Next Year, Shares Near Four-year Low

2 weeks from now

Sep 12, 2024 · Moderna expects to have $6 billion as cash on hand by 2024 end, which according to Jefferies analyst Michael Yee was at the lower end of its prior view of $6 billion to …

reuters.com

$1
OFF

Moderna Stock Drops On Plans To Cut $1.1B In R&D Costs

2 weeks from now

Sep 12, 2024 · Moderna said it expects the moves to lower expenses by $1.1 billion by 2027. ... $4.8 billion this fiscal year, with plans to cut spending to $3.6 to $3.8 billion by the end of fiscal …

investopedia.com

$18
OFF

Moderna's MRNA Technology Looks Undervalued Despite Lower …

2 weeks from now

2 days ago · Moderna's massive covid vaccine sales and prepayments left it with $18.2 billion in cash at the end of 2022, but that balance is steadily shrinking due to previous share repurchases (more than $5 ...

morningstar.com

$1.86
OFF

Moderna Posts Surprise Profit As Covid Vaccine Sales Impress, Cost …

2 weeks from now

Nov 7, 2024 · Revenue: $1.86 billion vs. $1 ... The company reiterated its full-year 2024 product sales guidance of roughly $3 billion to $3.5 billion. Last quarter, Moderna slashed its outlook …

nbcnewyork.com

$1
OFF

Moderna Lowers Full-Year Revenue Outlook, Plans To Cut Cash …

2 weeks from now

2 days ago · -- Moderna shares fell intraday Monday after the company cut its full-year revenue outlook while the drugmaker aims to reduce cash costs by $1 billion in 2025 amid its ongoing …

marketscreener.com

$1
OFF

Moderna: Fresh Sell-Off On Cost Cutting Initiatives Short-Term Outlook …

2 weeks from now

Sep 12, 2024 · Moderna plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs. ... guidance for full-year 2024 was downgraded from the ... In its release today, Moderna said it expected ...

seekingalpha.com

21%
OFF

Moderna’s Stock Slides 21% After Company Lowers Full-year Sales ...

2 weeks from now

Aug 1, 2024 · Moderna Inc.’s stock tumbled 21% Thursday, after the biotech company cut its sales guidance for 2024, offsetting a narrower-than-expected second-quarter loss and revenue …

marketwatch.com

$1
OFF

Moderna Shares Plunge On Plans To Cut $1.1 Billion In Costs ... - MSN

2 weeks from now

Moderna said it plans to "break even" on an operating cash cost basis with $6 billion in revenue in 2028. The company previously said it expects to break even and return to growth in 2026.

msn.com

16%
OFF

Moderna Stock Plummets 16% After £819.59M Guidance Cut… - Inkl

2 weeks from now

2 days ago · Massachusetts-based Moderna also highlighted its plans to speed up its cost-cutting program that will reduce company expenses by £819.59 million ($1 billion) in 2025 and …

inkl.com

25%
OFF

Moderna Trims Research Budget, Stock Falls To Lowest Level In 10 …

2 weeks from now

Sep 12, 2024 · In addition, Moderna has laid an updated financial framework, expecting 2025 revenue of $2.5B-$3.5B (consensus estimate: $3.95B) and a CAGR of more than 25% or more for 2026-2028, driven by new ...

seekingalpha.com

$1
OFF

Moderna Surprises The Street By Predicting A Bigger-than

2 weeks from now

2 days ago · The company also said it was speeding up and expanding a cost-cutting plan. It expects to cut cash costs by $1 billion in the new year, with additional cuts planned in 2026. …

marketbeat.com

FAQs about Moderna Lowers Full-Year Revenue Outlook, Plans to Cut Cash … Coupon?

How much money did Moderna make in 2024?

For 2024, Moderna said its product sales came in between $3 billion and $3.1 billion. Spikevax made up the majority of the tally at more than $3 billion, with mRESVIA making a "minimal" contribution, according to the company. It recorded revenue of $1.7 billion in the US and $1.3 billion to $1.4 billion in the rest of the world. ...

Is Moderna resetting its financial expectations?

The financial reset comes as the company’s vaccine sales continue to disappoint even modest expectations. Moderna said Thursday that it expects total revenue between $2.5 billion and $3.5 billion in 2025, below the current FactSet consensus estimate of $3.9 billion. ...

How much money will Moderna save this year?

Moderna now forecasts cash cost reductions of $1 billion this year, including cost of sales, research and development and selling, general & administrative expenses, as it accelerates and expands its previous cost efficiency programs. ...

How much will Moderna sell next year?

It projected sales of between $2.5 billion and $3.5 billion next year. It has said this year’s sales will range between $3 billion and $3.5 billion, down from its previous outlook of about $4 billion. ‘Financial Discipline’ “We are still dealing with a market of uncertainty,” Moderna Chief Financial Officer Jamey Mock said in an interview. ...

How much did Moderna make in 3rd quarter?

Moderna booked third-quarter sales of $1.86 billion, only slightly higher than the $1.83 billion in revenue it recorded during the same period a year ago. The vast majority of that total came from its Covid shot, including $1.2 billion in U.S. sales and roughly $600 million from international markets. ...

Why are Moderna shares down 20% this year?

Moderna shares are down 20% this year. In early August, the company slashed its 2024 revenue guidance by as much as 25%, citing low Covid-19 vaccine sales in Europe and tight competition in the U.S. The guidance cut raised questions about Moderna’s 2026 break-even target and spurred concerns the company could run out of cash. ...